Journal
VASCULAR HEALTH AND RISK MANAGEMENT
Volume 8, Issue -, Pages 533-539Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/VHRM.S28041
Keywords
transforming growth factor beta; pathway; Smads; non-Smads; atherosclerosis; myeloproliferative syndromes
Categories
Funding
- Instituto de Salud Carlos III, Spanish Ministry of Health (ISCIII) [PI080920, RD06/0014/1007]
Ask authors/readers for more resources
Transforming growth factor beta (TGF-beta 1) is a pleiotropic cytokine with many and complex effects in cell and tissue physiology. This is made possible by a very complex and interwoven signaling system, whose regulation continues to be the focus of a growing line of research. This complex regulation translates to a key role in cardiovascular physiology, hemostasis, and the blood-vessel interface. In accordance with this, the TGF-beta 1 pathway appears to be deregulated in related disorders, such as atherosclerotic vascular disease and myeloproliferative syndromes. It is expected that the growing amount of experimental and clinical research will yield medical advances in the applications of knowledge of the TGF-beta 1 pathway to diagnosis and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available